Home › Multiple Sclerosis › Tennessee
Pag-aaral pangklinika para sa Multiple Sclerosis sa Tennessee
6 pag-aaral para sa Multiple Sclerosis ang naghahanap ng mga kalahok sa mga site sa Tennessee.
Mga Lungsod sa Tennessee
Opisyal na teksto ng pag-aaral (English)
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Franklin
- TG Therapeutics Investigational Trial Site, Knoxville
- TG Therapeutics Investigational Trial Site, Mount Juliet
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06433752Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Hope Neurology- Site Number : 8400019, Knoxville
Nagre-recruitPhase 3
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07325292RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Alliance for Multispecialty Research Clinical, Knoxville
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07002034A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Hope Neurology, Knoxville
Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Neurology Clinic PC, Cordova
Nagre-recruitPhase 4
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07609719A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Neurology Clinic PC, Cordova
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT07225504Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.